SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Care-plan review) — Nelson Mandela — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientNelson Mandela
Date of birth1918-07-18
IdentifiersMRN HR-ML021-SYN-TD; SSN (made up) 000-21-6718
Document date2001-10-27
AuthorThandiwe Mokoena, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Follow-up six weeks after radiotherapy for prostate cancer. [S]

History of Present Illness

Mr. Mandela returns six weeks after finishing 37 fractions of radiotherapy, which he completed without a break. In the fourth week he developed urinary frequency, a weaker stream, and getting up twice a night, and radiation oncology started tamsulosin 0.4 mg in the evening; these symptoms are now improving, and he has had no burning, blood in the urine, or retention, and no dizziness on standing. In the last weeks of treatment his bowels became looser, two or three times a day with some urgency, and they are now settling to once or twice a day, with no bleeding. Asked about his bowels before treatment, he says they were regular, about once a day, as recorded at his wellness visit. His second leuprolide depot ran out about three weeks ago; hot flashes are fewer, and the tiredness he had during radiotherapy is lifting. His mood is good. He has resumed his morning walks. [S]

ElementDetail
Radiotherapy74 Gy in 37 fractions, completed six weeks ago
UrinaryFrequency and nocturia twice, improving on tamsulosin; no blood or burning
BowelLooser stools and mild urgency, settling; no bleeding
Androgen deprivationCompleted; last depot ran out three weeks ago; hot flashes fading

Review of Systems

SystemResultFinding
ConstitutionalPositiveTiredness from radiotherapy, improving; weight stable
GenitourinaryPositiveFrequency and nocturia twice, improving; no burning, blood, or retention
GastrointestinalPositiveStools once or twice a day, softer than before, with mild urgency; no bleeding
EndocrinePositiveOccasional hot flashes, fewer than before
NeurologicalNegativeNo dizziness on standing
PsychiatricNegativeMood good; PHQ-2 score 0

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Bicalutamide 50 mg oral tablet, one tablet by mouth once daily for four weeks, to block the testosterone flare at the start of leuprolideOne tablet once daily for four weeksOral route2001-04-14 to 2001-05-12completedS
Leuprolide acetate 22.5 mg injection (three-month depot), intramuscular, two doses twelve weeks apart (the second given at a primary care visit), about six months of androgen deprivation with radiotherapyOne injection every twelve weeks, two dosesIntramuscular route2001-04-21 to 2001-10-06completedS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2001-04-14activeS
Tamsulosin 0.4 mg oral capsule, one capsule by mouth once daily after the evening meal, for urinary frequency during radiotherapyOne capsule once daily in the eveningOral route2001-08-18activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2001-10-27Body height183cmS
2001-10-27Body weight81.4kgS
2001-10-27Body mass index (BMI) [Ratio]24.3kg/m2S
2001-10-27Systolic blood pressure128mm[Hg]S
2001-10-27Diastolic blood pressure74mm[Hg]S
2001-10-27Heart rate68/minS
2001-10-27Respiratory rate14/minS
2001-10-27Body temperature36.7CelS
2001-10-27Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2001-10-27Prostate specific Ag [Mass/volume] in Serum or Plasma0.4ng/mL<=4 ng/mLNormalS
2001-10-27Testosterone [Mass/volume] in Serum or Plasma38ng/dL264 to 916 ng/dL in adult men; below 50 ng/dL is the castrate target on androgen deprivationLowS
2001-10-27International Prostate Symptom Score [IPSS]12{score}S
2001-10-27Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 2001-10-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell
CardiovascularRegular rhythm; blood pressure 128/74 mm Hg seated; no ankle swelling
AbdomenSoft and non-tender; bladder not palpable
SkinMild hyperpigmentation over the treated area only; skin intact

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate canceractiveconfirmed C61S — Synthetic grade, PSA, core count, stage, and risk group; the PSA rise, the biopsy-proven localized cancer that was not high grade, hormone therapy, and curative radiotherapy are from his doctors' and spokeswoman's public statements (D).
Hormone-sensitive prostate canceractiveconfirmed Z19.1S — Synthetic status in the modern episode.
Short-term androgen deprivation therapy (six months, leuprolide), with monitoring of testosterone, bone density, metabolic and cardiovascular risk, hot flashes, mood, and cognitionactiveconfirmed Z79.899S — Synthetic androgen deprivation plan; Z79.899 is used because ICD-10-CM has no specific code for GnRH agonist therapy.
History of pulmonary tuberculosis, treated, with no symptoms sinceresolvedconfirmed Z86.11S — The 1988 tuberculosis is documented (D); the coding and the statement that it has not recurred are synthetic.
Personal history of external beam radiotherapy to the prostateactiveconfirmed Z92.3S — Synthetic: recorded after the course of radiotherapy finished.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryPSA after radiotherapyEvery 6 to 12 months for 5 years, then yearlyCompleted today0.4 ng/mL, first value after radiotherapy; next in six months
LaboratoryTestosterone recoveryWith PSA after androgen deprivation endsCompleted today38 ng/dL, not yet recovered
LaboratoryHemoglobin A1c or fasting glucose, and lipid panelYearly after androgen deprivationDueDue in four months, one year after baseline
ImagingBone density (DXA)Every 1 to 2 years after androgen deprivationUp to dateBaseline six months ago; next in one to two years
ExaminationDigital rectal examinationYearly after curative treatmentDueNot useful this soon after radiotherapy; due in one year
ExaminationBlood pressure and cardiovascular assessmentEvery visit while on androgen deprivation and afterCompleted today128/74 mm Hg seated; no dizziness on standing on tamsulosin
SurveyUrinary symptoms (IPSS)Every follow-up visit, particularly the first two yearsCompleted todayIPSS 12, up from 7 before treatment; improving on tamsulosin
SurveyBowel function after radiotherapyEvery visit after radiotherapyCompleted todaySofter stools once or twice a day with mild urgency, settling; no bleeding
SurveyBowel baseline missed before radiotherapyBaseline before radiotherapyDeferredNot asked at the visit before radiotherapy, a deviation from the protocol. The wellness visit five weeks before that had recorded regular, formed stools once a day, and he confirms this today, so a baseline was available and no harm resulted. The bowel question is now on the pre-radiotherapy checklist
SurveySexual functionPeriodically after treatmentCompleted todayReviewed; expected recovery after androgen deprivation explained; no treatment requested
Medication safetyHot flashes and fatigueEvery visit until androgen deprivation effects resolveCompleted todayFewer hot flashes; fatigue from radiotherapy improving
SurveyDistress and depression screen (PHQ-2)At intervalsCompleted todayPHQ-2 score 0
SurveyCognitionPeriodically after androgen deprivationUp to dateMini-Cog 5 of 5 at the wellness visit; no change reported
Self-managementSurvivorship care plan and lifestyleAfter treatment; lifestyle every visitCompleted todayWritten plan given; walking resumed; no tobacco

Goal progress:

Immunizations given today: High-dose influenza vaccine, this season [S]

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part III: Principles of Radiation and Future Directions. J Urol 2022;208(1):26-33 (2022); Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026)

Follow-up: Primary care in three months to review tamsulosin and urinary and bowel symptoms. PSA and testosterone in six months. Radiation oncology review in six weeks, three months after treatment. Influenza vaccine given today. [S]